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Abstract Relationship between the chronic and excessive ex-
posure to glucocorticoids and the development of psychiatric
disorders, including depression, has been described in the liter-
ature. We decided to investigate whether a combination of
agents with antidepressant activity (i.e., imipramine, ketamine,
and Zn2+) may influence/reverse the depressogenic effect of
dexamethasone therapy. The antidepressant-like effect was
assessed by the forced swim test in adult mice. The inhibitory
activity of dexamethasone was dose-dependent: only the
highest tested dose of the glucocorticoid (i.e., 64 μg/kg) given
as a single injection increased immobility time, whereas 16 μg/
kg/day of dexamethasone administered repeatedly (for 14 days)
induced a significant alteration in animal behavior. Both the
acute or sub-chronic administration of the active doses of imip-
ramine (10 mg/kg), Zn2+ (30mg/kg), and ketamine (30 mg/kg),
and the combinations of their per se inactive doses reversed the
inhibitory activity of dexamethasone (16 μg/kg/day) adminis-
tered for 14 consecutive days. Whereas a single injection of an
inhibitory dose of dexamethasone (64 μg/kg) was not able to
abolish the antidepressant effect of imipramine (5 mg/kg), Zn2+
(10 mg/kg), and imipramine-Zn2+ combination (2.5 and
5 mg/kg, respectively) given once a day for 14 consecutive
days. Our findings indicate that the chronic dexamethasone
injection procedure has some potential as an animal model of
depression and they further support the theory of interplay be-
tween glutamatergic neurotransmission and the chronic or ex-
cessive exposition to glucocorticoids.
Keywords Dexamethasone . Antidepressant-like activity .
Forced swim test . Mice
Introduction
Organism reaction to stress is an important adaptive response
that mobilises the organism and re-establishes homeostasis.
Neuronal, endocrine and immune mechanisms are turned on,
including activation of the hypothalamic–pituitary–adrenal
(HPA) axis, and an increased secretion of glucocorticoids is
noted. Though indispensable for coping with stressful events,
glucocorticoids may have a negative effect on both structure
and function of brain cells. The hippocampus, as highly abun-
dant in glucocorticoid receptors, seems to be particularly vul-
nerable to stress (Bosch et al. 2012; McEwen et al. 1969). In
consequence, chronic and excessive exposure to glucocorti-
coids may lead to development of psychiatric disorders, in-
cluding depression. In fact, depression was reported in psy-
chiatrically healthy patients receiving chronic high doses of
glucocorticoids as well as in the people with Cushing’s syn-
drome (Brown et al. 1999). On the other hand, patients with
endogenous depression present HPA axis hyperactivity (ele-
vated cortisol and adrenocorticotropin hormone levels, en-
largement of adrenal glands) and failure to suppress cortisol
in response to the dexamethasone suppression test (Stetler and
Miller 2011). Some of the antidepressant agents (i.e., desipra-
mine, fluoxetine) influenced the neuroendocrine substrates
that regulate cortisol secretion (Antonioli et al. 2012;
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Okuyama-Tamura et al. 2003). Though it is still not obvious
whether the high cortisol level seen in depressed patients plays
a causal role in depression or whether it is a “by-product” of
depression. After exposure to chronic stress or administration
of glucocorticoids, animals show behavioral changes associ-
ated with depression such as: anhedonia, food intake disorder,
cognitive deficits, decrease in sexual activity, increased immo-
bility time in the forced swim test (FST) and the tail suspen-
sion test (TST), elevated anxiety levels (Feldmann et al. 2008;
Gorzalka and Hanson 1998; Gourley et al. 2008; Gregus et al.
2005; Zhao et al. 2008). Similarly, biochemical (altered glu-
cocorticoid receptor concentration, increased glutamate level,
serotonin deficiency, modulation of 5-HT1A and 5-HT2A re-
ceptors function) (Ago et al. 2008; Fernandes et al. 1997; Li
et al. 2014), morphological (neuronal remodeling in the hip-
pocampus, amygdala and medial prefrontal cortex) (Vyas
et al. 2002; Wellman 2001; Woolley et al. 1990), and func-
tional changes (reduction of neurogenesis in the dentate gyrus
of the hippocampus) (Pham et al. 2003) are observed. It has
been shown that the glucocorticoid receptor antagonists may
ameliorate the behavioral and neurochemical alterations of
depression (Iijima et al. 2010). Moreover, Kitayama et al.
(1988) have found that that chronic treatment with imipramine
may increase the regulation of glucocorticoid receptor. Based
on the research of Biagini et al. (1993), imipramine also an-
tagonized the behavioral and endocrine responses induced by
repeated exposure to unpredictable stress in the rat model. It
can, therefore, be assumed that the modelled depression and
the associated increase in corticosterone level may be con-
trolled by this tricyclic antidepressant.
Chronic corticosterone-injected rodents have been pro-
posed as an animal model of depression that mimics the dys-
function of the HPA axis in depression. Several studies have
indicated that the repeated corticosterone administration elicit
an increase in immobility behavior during the FSTand TST in
male and female rodents without affecting their overall loco-
motion (Ago et al. 2008; Gregus et al. 2005; Johnson et al.
2006; Koike et al. 2013). Though, Meyer et al. (2012) pointed
out that the chronic corticosterone-injected model is not suit-
able for the adolescent rats.
The results of our previous experiments revealed that the
single and 7-day administration of dexamethasone lead to a
depressogenic effect in adult mice (Wróbel et al. 2014).
Similarly, Li et al. (2014) reported that neonatal dexametha-
sone exposure caused depression-like behavior in juvenile
mice, suggesting that this paradigm may be a new animal
model of pediatric depression. Though there are many studies
on the effect of antidepressants in naïve animals, it seems to be
more appropriate to evaluate the effects of the drugs in models
that mimic symptoms of human depression. Therefore, we
decided to investigate whether a combination of agents with
antidepressant activity (i.e., imipramine—a classic tricyclic
antidepressant, ketamine—a noncompetitive NMDA receptor
antagonist, and Zn2+—the divalent inorganic inhibitor of the
distinct binding site at the NMDA receptor complex) may




The study was conducted on adult male Albino Swiss mice
(weighting initially 18–25 g). A natural light/dark cycle, tem-
perature of 23±1 °C and humidity of 50–60 % were main-
tained. Food and water were provided ad libitum. All experi-
mental procedures were carried out between 8 a.m. and 1 p.m.
Mice were experimentally naïve and tested once. Ninety four
groups of animals were used in the study, each one consisted
of 12–15 animals. All procedures were conducted in accor-
dance with the European Communities Council Directive of
22 September 2010 (2010/63/EU) and Polish legislation acts
concerning animal experimentations. The experimental proce-
dures and protocols were approved by the First Local Ethics
Committee at the Medical University of Lublin.
Drugs
The following drugs were used: dexamethasone (Jelfa,
Poland) , imipramine (Polpharma, Poland) , z inc
hydroaspartate (Farmapol, Poznań, Poland), and ketamine
(Parke-Davis, Berlin, Germany). Imipramine, zinc
hydroaspartate, and ketamine were administered intraperito-
neally (i.p.), whereas dexamethasone was given subcutane-
ously (s.c.), at 10 ml/kg in water.
Locomotor activity
The locomotor activity of animals was assessed with the aid of
a Digiscan apparatus: an Optical Animal Activity Monitoring
System (Omnitech Electronics, Inc., Columbus, Ohio, USA).
Activity chambers consisting of clear acrylic open field boxes
were located in a room lit by a dim red light. The Digiscan
system monitored animal locomotor activity via a grid of in-
visible infrared light beams. Cumulative counts of beams in-
terruptions were recorded in 15 min intervals using
OMNIPRO software. Prior to behavioral analysis, subjects
were placed into activity chambers for a 15-min habituation
period. Experiments were performed in a sound-proof room.
Horizontal activity was assessed. This was defined as the total
number of beam interruptions that occurred in the horizontal
sensor during one hour of measurement.
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Forced swim test
The studies were carried out on mice according to the
method of Porsolt et al. (1977). Mice were placed indi-
vidually into glass cylinders (height 25 cm, diameter
10 cm) containing 10 cm of water, maintained at 23–
25 °C. Animals were removed and returned to their
home cages after 1 min in water. Twenty four hours
later, they were again placed in the cylinder. Mice were
left there for 6 min. After the first 2 min, the total
duration of immobility was measured during the follow-
ing 4-min test. The mouse was judged to be immobile
when it remained floating passively, performing slow
motion movements to keep its head above the water.
Experiments
Experiment 1: Determination of the effect of dexamethasone
on the immobility time of mice in the FST and their
spontaneous locomotor activity
Dexamethasone was given in a single dose (4, 16 or 64 μg/kg)
or for 14 days at the doses of 4 or 16 μg/kg/day. Locomotor
activity or immobility time was registered 3.5 h after a single
or 48 h after the last injection (in the 14-day experiment) of
dexamethasone. The time intervals between administration of
dexamethasone and the behavioral test were selected on the
basis of our previous studies on the behavioral effects of dexa-
methasone (Wróbel et al. 2014) and were confirmed in the
preliminary experiments.
Experiment 2: Evaluation of the influence of a sub-chronic
administration of zinc or the acute injections of imipramine
or ketamine, and their combinations on the 14-day
dexamethasone treatment in the FST
Dexamethasone was given at the dose of 16 μg/kg/day for
14 days. Locomotor activity or immobility time were regis-
tered 48 h after the last injection of the glucocorticoid.
Antidepressant agents were given in the following scheme:
imipramine (5 or 10 mg/kg) and ketamine (30 mg/kg) were
administered only once 1 h and 30 min prior to the behavioral
tests, respectively, and zinc hydroaspartate (15 or 30 mg/kg)
was injected three times (sub-chronic treatment, i.e., 24,
5 and 1 h before the behavioral tests). Dosage of zinc
referred to pure zinc ions. The doses of all substances
as well as the time interval between their administration
and the behavioral tests were taken from the literature
(Browne and Lucki 2013; Nowak et al. 2003; Wróbel
et al. 2014) and were confirmed/adjusted in our labora-
tory in preliminarily experiments.
Experiment 3: Evaluation of the influence of a chronic
administration of imipramine, zinc, and their combination
on a single injection of dexamethasone in the FST
Imipramine (2.5 or 5 mg/kg/day) and zinc hydroaspartate (5 or
10 mg/kg/day) were given for 14 days, while dexamethasone
(64 μg/kg) was administered only once. Locomotor activity or
immobility time were registered 48 h after the last injection of
imipramine and/or zinc hydroaspartate. Dexamethasone was
given 3.5 h prior to the behavioral tests.
Experiment 4: Evaluation of the influence of a chronic
administration of imipramine and zinc given in combination
with ketamine on a single injection of dexamethasone
in the FST
Per se inactive doses of imipramine (2.5 mg/kg/day) and zinc
hydroaspartate (5 mg/kg/day), were given for 14 days. An
inhibitory dose of dexamethasone (64 μg/kg) and an antide-
pressant dose of ketamine (30 mg/kg) were administered only
once. Locomotor activity or immobility time were registered
48 h after the last injection of imipramine and/or zinc
hydroaspartate. Dexamethasone and ketamine were given
3.5 h and 14 days prior to the behavioral tests, respectively.
Statistical methods
The obtained data were assessed by the t-test, one-way or two-
way analysis of variance (ANOVA) followed by Bonferroni’s
post hoc test, depending on the experimental design. All re-
sults are presented as the means±standard error of the mean
(SEM). P<0.05 was considered a statistically significant
difference.
Results
The effect of dexamethasone on the immobility time
of mice in the FST and their spontaneous locomotor
activity
Sixty four μg/kg of dexamethasone given as a single injection
considerably increased the immobility time of the animals in
the FST (one-way ANOVA: F3,56=141.7, P<0.0001). The
doses of 4 and 16 μg/kg appeared to be too low to influence
the behavior of mice in this experiment. Animals subjected to
a 14-day treatment with dexamethasone at a dose of 16 μg/kg/
day spent significantly less time swimming in comparison to
the control group (one-way ANOVA: F2,42 = 71.39,
P<0.0001; Fig. 1a). Neither single nor repeated (14-day) ad-
ministration of dexamethasone in the tested doses sig-
nificantly changed the spontaneous locomotor activity of
mice (one-way ANOVA: F3,56=2.100, P=0.1105 and F2,
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42=2.664, P=0.0815 for the single and repeated admin-
istration, respectively; Fig. 1b).
The influence of a sub-chronic administration of zinc
or the acute injections of imipramine or ketamine,
and their combinations on the 14-day dexamethasone
treatment in the FST
As illustrated in Fig. 2c and d, the active doses of the tested
antidepressant agents (i.e., 10, 30, and 30 mg/kg for imipra-
mine, Zn2+, and ketamine, respectively), that were selected on
the naïve animals, abolished an inhibitory effect of the repeat-
ed treatment with dexamethasone. The combinations of imip-
ramine (5 mg/kg) with zinc (15 mg/kg), imipramine (5 mg/kg)
with ketamine (15 mg/kg), and zinc (15 mg/kg) with ketamine
(15 mg/kg) reversed the inhibitory activity of dexamethasone
administered at a dose of 16 μg/kg once a day for 14 consec-
utive days (two-way ANOVA: F1,54=11.22, P=0.0015 for
imipramine-zinc interaction; one-way ANOVA: F2,42=
24.60, P< 0.0001 and F2 ,42 = 39.06, P< 0.0001 for
imipramine-ketamine and zinc-ketamine combinations,
respectively). These combinations appeared to be not active
in the naïve mice (Fig. 2a and b).
Influence of a chronic administration of imipramine, zinc,
and their combination on a single injection
of dexamethasone in the FST
A single injection of an inhibitory dose of dexamethasone
(64 μg/kg) was not able to abolish the antidepressant effect
of imipramine (5 mg/kg), zinc (10 mg/kg), and imipramine-
zinc combination (2.5 and 5 mg/kg, respectively) given once a
day for 14 consecutive days (one-way ANOVA: F2,42=25.62,
P<0.0001 and F2,42=19.68, P<0.0001 for imipramine and
zinc, respectively; two-way ANOVA: F1,56 = 59.54,
P<0.0001 for imipramine-zinc interaction; Fig. 3b). The
imipramine-zinc combination (2.5 and 5 mg/kg, respectively)
was not active in the naïve mice (Fig. 3a).
Influence of a chronic administration of imipramine
and zinc given in combination with ketamine on a single
injection of dexamethasone in the FST
An antidepressant effect of a single injection of ketamine
(30 mg/kg) lasted shorter than 14 days (t-test: t28=1.045, P=
3.049). Neither imipramine (2.5 mg/kg/day) nor zinc
(5 mg/kg/day) administered for 14 consecutive days at the
sub-active doses selected o the naïve mice potentiated and/or
prolonged the activity of ketamine, which was illustrated in
Fig. 3b (two-way ANOVA: F1,56=2.62, P=0.1112 and F1,56=
1.43, P=0.2373 for imipramine-ketamine and zinc-ketamine
interactions, respectively).
The influence of a single administration
of dexamethasone, imipramine, zinc, ketamine, and their
combinations on the spontaneous locomotor activity
of mice
None of the tested agents given alone or in combinations
according to the schemes applied in the Experiments 2, 3
and 4, influenced the locomotor activity of animals (P>0.05,
data not shown).
Discussion
According to the literature (e.g., Brown et al. 1999), dexa-
methasone can induce a variety of psychiatric symptoms rang-
ing from depression to mania and affective psychosis. Acute
administration of this glucocorticosteroid causes neuronal
death (accompanied by extensive sublethal neuronal damage)
of granule cells in the dentate gyrus, pyramidal neurons in the
CA1 and CA3 subfields of the hippocampus and
striatopallidal neurons in the dorsomedial caudate putamen
Fig. 1 Effect of acute (4, 16 or 64 μg/kg) and 14-day (4 or 16 μg/kg)
treatment with dexamethasone on a the behavior of mice in the FSTand b
the spontaneous locomotor activity in mice. Dexamethasone was given
s.c. The behavioral tests were performed 3.5 or 48 h after a single or the
last (in the chronic experiment) injection of dexamethasone, respectively.
The values represent the mean+SEM (n=15 mice per group).
***P<0.001 versus control (s.c.) (Bonferroni’s post hoc test)
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(Hassan et al. 1996; Haynes et al. 2001). Hippocampus and
striatum are the brain areas that showmorphological abnormal-
ities in patients with mood disorders (Bremner et al. 2000;
Rogers et al. 1998). Moreover, Haynes et al. (2004) reported
the chronic (but not acute) pretreatment with different classes of
antidepressants (but not with the psychoactive agents devoid of
antidepressant potential) attenuated dexamethasone-induced
neuronal damage. Then again, we previously demonstrated that
both single and repeated administration of dexamethasone were
able to modify the activity of antidepressant drugs from various
pharmacological groups (Wróbel et al. 2014).
In the present study, the dexamethasone-injected mice sub-
jected to the Porsolt test spent significantly more time being
immobile compared to the vehicle-treated animals, which was
indicative of their depressive behavior and appeared to be in
line with the outcomes of our preceding experiments (Wróbel
et al. 2014) and with the results obtained by Sigwalt et al.
(2011). Just like in the repeated corticosterone injection para-
digm, the observed effect was dose-dependent (Gregus et al.
2005; Johnson et al. 2006), but in our case, it appeared after
both single and repeated administrations. Nevertheless, basing
on the obtained results we are able to agree with the other
authors (Gregus et al. 2005; Johnson et al. 2006) that the
amount of the glucocorticoid and duration of treatment seems
to be crucial determinants for the expression of a depressive
phenotype in the forced-swim test. The results presented herein
have not been confounded by the altered activity level of the
tested animals, since the dexamethasone-treated mice showed
no significant differences in overall spontaneous locomotor ac-
tivity. For the same reason, it is highly unlikely that an increase
in the immobility time observed in the FST could only be a
simple consequence of weight loss in animals (Johnson et al.
2006; Marks et al. 2009; Zhao et al. 2008). Sigwalt et al. (2011)
also emphasized that animals’ response to dexamethasone treat-
ment seemed not to be influenced by their motor dysfunctions.
Though the further studies providing the biochemical expla-
nation of the outcomes of our studies need to be performed, Li
et al. (2014) have suggested that the behavioral abnormalities at
juvenile and adult mice observed after neonatal dexamethasone
exposition, may be the consequence of abnormalities in
glutamatergic and GABAergic neurotransmissions. Kamphuis
et al. (2003) found that exposure to dexamethasone during the
Fig. 2 Influence of the acute injections of imipramine (5 or 10 mg/kg;
IMI), zinc (15 or 30 mg/kg; Zn), ketamine (15 or 30 mg/kg; KET), and
their combinations on the 14-day dexamethasone (16 μg/kg/day; DEX)
treatment in the FST inmice. The behavioral test was performed 48 h after
the last s.c. injection of dexamethasone. Imipramine and ketamine were
administered i.p. only once 1 h and 30 min prior to the behavioral tests,
respectively, and zinc hydroaspartate was injected i.p. three times (i.e., 24,
5 and 1 h before the behavioral tests). The experiments were performed
on the naïve (a and b) and dexamethasone-treated (c and d) andmice. The
values represent the mean+SEM (n=13–15 mice per group).
^^^P<0.001 versus dexamethasone (Bonferroni’s post hoc test),
###P<0.001 versus dexamethasone and respective antidepressant(s)
(Bonferroni’s post hoc test), ***P<0.001 versus control (t-test or
Bonferroni’s post hoc test)
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neonatal period leads to a reduction in the GluN2B subunit
levels of the NMDA receptor complex in hippocampus which
may in the later life be implicated in the development of psy-
chiatric diseases.
The outcomes of multiple pre-clinical and clinical studies
have indicated the role of zinc in mood disorders. Apart from
its own antidepressant-like properties demonstrated in animal
tests and models (FST, TST) (Kroczka et al. 2000; Rosa et al.
2003), olfactory bulbectomy (Nowak et al. 2003), chronic un-
predictable stress (Cieślik et al. 2007), and chronic mild stress
(Sowa-Kućma et al. 2008), zinc also potentiated the activity of
fluoxetine, paroxetine, citalopram, and bupropion (Cunha et al.
2008; Szewczyk et al. 2009). Zinc as an antagonist of the
NMDA receptor complex and an agonist of the adenosine A1
and A2 receptors (Amico-Ruvio et al. 2011; Lobato et al. 2008)
modulates glutamatergic, GABAergic, and glycinergic neuro-
transmissions (Mocchegiani et al. 2005) and may activate me-
tabotropic GPR39 receptor (Holst et al. 2007). Special attention
has been paid to connection between zinc deficiency and devel-
opment of depression-like behavior in animals (Młyniec et al.
2012) and its correlation with hyperactivation of the HPA axis
(Młyniec et al. 2012; Takeda et al. 2012; Watanabe et al. 2010).
It has been shown that zinc-deficient diet induced a high serum
corticosterone level in rats (Takeda et al. 2012), which may in
turn be linked to glutamate accumulation and its excitotoxicity
(Takeda and Tamano 2010). On the other side, corticosterone
has been able to exert hippocampal zinc dyshomeostasis
(Takeda and Tamano 2012). In our experiments, it appeared that
the triple injections (i.e., 24, 5 and 1 h before the behavioral
tests) of the lowest antidepressant dose of zinc (selected on the
naïve mice) were potent enough to abolish the inhibitory effect
induced by a 14-day treatment with dexamethasone at a daily
dose of 16 μg/kg but an acute inhibitory dose of this glucocor-
ticoid did not manage to reverse an antidepressant action of zinc
given to animals for 2 weeks. Moreover, we noticed a stronger
antidepressant effect of combination of zinc and imipramine in
the repeatedly dexamethasone-injected animals but not in the
naïve ones. The synergistic effect of these agents with the anti-
depressant potential was not recorded when given chronically to
naïve mice in the sub-effective doses for 14 consecutive days.
Nevertheless, such a combination exerted an effect strong
enough to prevent the inhibitory activity of a single active dose
of dexamethasone (i.e., 64μg/kg). According to literature data, a
repeated treatment with zinc alone or in combination with imip-
ramine induces a significant increase in the BDNFmRNA level
in the chronically stressed animals (Cieślik et al. 2011).
Ketamine, the other compound investigated in our experiment
that acts through the glutamatergic neurotransmission, belongs to
the noncompetitive NMDA receptor antagonists. Though its ef-
ficacy and safety profile still needs further confirmation, keta-
mine has appeared to be effective in patients with major depres-
sion, including the refractory cases (Murrough et al. 2013; Rao
and Andrade 2010). The antidepressant activity of ketamine
along with the mechanisms responsible for this effect have been
studied in different animal models of depression, including the
repeated corticosterone-injected rodents (Aan Het et al. 2012;
Koike et al. 2013; Krystal et al. 2013). Koike et al. (2013) found
that a subanesthetic dose of ketamine reduced the increased im-
mobility time of the repeated corticosterone-injected rats. We
demonstrated that a single administration of the lowest antide-
pressant dose of ketamine (selected on the naïve mice) sup-
pressed inhibitory behavior induced by the chronic exposure to
dexamethasone (16 μg/kg/day), while the acute or sub-chronic
injections of ketamine-imipramine and ketamine-zinc combina-
tions appeared to exert a synergistic effect in the repeatedly
dexamethasone-injected animals but not in the naïve ones.
Similar to our results, Li et al. (2014) reported that another
NMDA receptor antagonist (i.e., Ro 63-1908, that binds specif-
ically to the GluN2B subunit) prevented the depression-like be-
havior in juvenile mice after neonatal dexamethasone exposure.
The authors presumed that the observed depressive behavior of
juvenile animals could be a consequence of the alterations in
glutamatergic transmission induced by the glucocorticoid.
According to the literature (Aan Het et al. 2012; Krystal
et al. 2013), the clinical benefits of a single dose of ketamine
Fig. 3 Influence of a single injection of dexamethasone (64μg/kg; DEX)
on the 14-day administration of imipramine (2.5 or 5 mg/kg/day; IMI),
zinc (5 or 10 mg/kg/day; Zn), their combination, and the combination
with a single injection of ketamine (30 mg/kg; KET) in the FST.
Dexamethasone was given s.c. 3.5 h before the behavioral test. The
behavioral test was performed 48 h after the last i.p. injection of
imipramine and/or zinc and 14 days after i.p. administration of
ketamine. The values represent the mean+SEM (n=12–15 mice per
group). ^^^P<0.001 versus dexamethasone (Bonferroni’s post hoc test),
###P<0.001 versus dexamethasone and respective antidepressants
(Bonferroni post hoc test), ***P<0.001 versus control (t-test or
Bonferroni’s post hoc test)
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may last as briefly as 1 or 2 days or as long as more than
2 weeks. In experiments performed by Zhang et al. (2014) a
single dose of R-ketamine produced rapid and long-lasting
(7 days) antidepressant effects in juvenile mice exposed neo-
natally to dexamethasone. The authors have suggested that
antagonism of the NMDA receptor complex may promote a
rapid antidepressant action of R-ketamine but most probably,
it is not responsible for the longevity of the antidepressant
effect. Li et al. (2014) provided further evidence of the rapid
onset and enduring antidepressant effects of ketamine, which
managed to ameliorate anhedonia in juvenile mice after neo-
natal dexamethasone exposure. The antidepressant effects
were recorded at 46 h after a single ketamine dose and the
ketamine-induced increase in sucrose intake persisted for
8 days. The outcomes of our experiments did not confirm a
2-week persistence of an antidepressant effect of a single dose
of ketamine. It was not potentiated and/or prolonged by imip-
ramine or zinc, either.
Conclusion
Our findings indicate that the repeated dexamethasone injec-
tion procedure may constitute a potential model to study the
expression of depressive symptomatology influenced by glu-
cocorticoids. However, the confirmatory studies are required.
First of all, the procedure should also be assessed in females,
since it has been proven that males and females may respond
in a different manner in behavioral models, and males may be
more susceptible to the behavioral and neural consequences of
repeated stress (Kalynchuk et al. 2004). Moreover, it would be
interesting to compare the effects of the repeated dexametha-
sone injection observed in juvenile and adult subjects. At last,
our results further support the theory of interplay between
glutamatergic neurotransmission and the chronic or excessive
exposition to glucocorticoids in behavioral alterations relevant
to depressive symptoms.
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